(MNOV)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
| Name | Position |
|---|---|
| Dr. David H. Crean M.B.A., Ph.D. | Chief Business Officer |
| Dr. Kazuko Matsuda M.D., M.P.H., Ph.D. | Chief Medical Officer & Director |
| Dr. Yuichi Iwaki M.D., Ph.D. | Co-Founder, President, CEO & Chairman |
| Mr. Jason J. Kruger CPA | CFO & Principal Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-10 | 10-K | mnov-20251231.htm |
| 2025-12-05 | S-3 | d17865ds3.htm |
| 2025-11-12 | 10-Q | mnov-20250930.htm |
| 2025-09-26 | CORRESP | filename1.htm |
| 2025-08-22 | S-1 | d163359ds1.htm |
| 2025-08-14 | 10-Q | mnov-20250630.htm |
| 2025-08-01 | 8-K | d84145d8k.htm |
| 2025-06-18 | 8-K | mnov-20250617.htm |
| 2025-05-13 | 10-Q | mnov-20250331.htm |
| 2025-04-28 | DEFA14A | notice_card_2025_defa14a.htm |